Yunnan Baiyao Group Co.,Ltd Just Missed Earnings - But Analysts Have Updated Their Models
Yunnan Baiyao Group Co.,Ltd Just Missed Earnings - But Analysts Have Updated Their Models
Yunnan Baiyao Group Co.,Ltd (SZSE:000538) missed earnings with its latest third-quarter results, disappointing overly-optimistic forecasters. Yunnan Baiyao GroupLtd missed earnings this time around, with CN¥9.5b revenue coming in 2.4% below what the analysts had modelled. Statutory earnings per share (EPS) of CN¥0.63 also fell short of expectations by 17%. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
雲南白藥集團有限公司(SZSE:000538)在最新的第三季度業績中未達到盈利預期,令那些過度樂觀的預測者感到失望。這一次雲南白藥集團未能達到盈利預期,營業收入爲95億元,低於分析師模擬的2.4%。每股收益爲0.63元人民幣,也低於預期的17%。分析師通常會在每份業績中更新他們的預測,我們可以從他們的估計中判斷公司的情況是否有變化,或者是否有任何需要注意的新問題。因此,我們收集了最新的業績後的法定共識預期,以了解明年可能會發生什麼。

After the latest results, the 14 analysts covering Yunnan Baiyao GroupLtd are now predicting revenues of CN¥44.2b in 2025. If met, this would reflect a decent 12% improvement in revenue compared to the last 12 months. Per-share earnings are expected to climb 18% to CN¥2.85. In the lead-up to this report, the analysts had been modelling revenues of CN¥44.3b and earnings per share (EPS) of CN¥2.83 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
在最新的結果公佈後,現有14位分析師對雲南白藥集團有限公司預測2025年的營業收入爲442億元人民幣。如果達到這一目標,與過去12個月相比,這將反映出營業收入的不錯增長12%。每股收益預計將增長18%,達到2.85元人民幣。在此報告公佈之前,分析師一直在模擬2025年的收入爲443億元人民幣,每股收益爲2.83元人民幣。因此,可以明顯看出,儘管分析師已更新他們的預測,但在最新結果後對業務的預期並沒有發生重大變化。
It will come as no surprise then, to learn that the consensus price target is largely unchanged at CN¥66.51. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Yunnan Baiyao GroupLtd at CN¥73.00 per share, while the most bearish prices it at CN¥54.20. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.
毫無疑問,共識價格目標基本上保持在66.51元人民幣不變。然而,只專注於一個價格目標可能不明智,因爲共識目標實際上是分析師價格目標的平均。因此,一些投資者喜歡查看估計範圍,以查看公司估值上是否存在不同意見。目前,最看好的分析師認爲雲南白藥集團股票價值73.00元人民幣,而最看淡的價格則爲54.20元人民幣。由於估值範圍較窄,分析師顯然對他們認爲該業務價值有着類似的看法。
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Yunnan Baiyao GroupLtd's past performance and to peers in the same industry. The analysts are definitely expecting Yunnan Baiyao GroupLtd's growth to accelerate, with the forecast 9.8% annualised growth to the end of 2025 ranking favourably alongside historical growth of 5.8% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 13% per year. So it's clear that despite the acceleration in growth, Yunnan Baiyao GroupLtd is expected to grow meaningfully slower than the industry average.
這些估計是有趣的,但在比較預測時,將更廣泛的背景畫出可能很有用,包括與雲南白藥集團有限公司過去的業績以及同行業的同行。分析師絕對期待雲南白藥集團有限公司的增長加速,預計到2025年底,9.8%的年增長率將在過去五年的5.8%的歷史增長率之上名列前茅。相比之下,我們的數據顯示,在同一行業的其他公司(得到分析師關注)預計每年增長13%的營業收入。因此,儘管增長加速,但很明顯,雲南白藥集團有限公司預計增長速度將低於行業平均水平。
The Bottom Line
最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at CN¥66.51, with the latest estimates not enough to have an impact on their price targets.
最明顯的結論是,最近業務前景沒有發生重大變化,分析師保持他們的盈利預測穩定,與先前的估計一致。正面的是,收入預測沒有發生重大變化;儘管預測意味着它們的表現將不如更廣泛的行業。一致的價格目標保持在66.51人民幣,最新預測不足以對其價格目標產生影響。
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Yunnan Baiyao GroupLtd analysts - going out to 2026, and you can see them free on our platform here.
這麼說吧,公司盈利的長期軌跡比明年更重要。我們有來自多位雲南白藥集團有限公司分析師的預估,到2026年,您可以在我們的平台上免費查看。
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Yunnan Baiyao GroupLtd that you should be aware of.
不要忘記可能仍然存在風險。例如,我們已經確定了雲南白藥集團有限公司的一個警示標誌,您應該注意。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。